| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,203 | 31,520 | -7,382 | -15,566 |
| Depreciation and amortization | NaN | 0 | 0 | 0 |
| Non-cash lease cost | 226 | 214 | 283 | 551 |
| Impairment of assets | NaN | 0 | 587 | NaN |
| Share-based compensation | 1,114 | 1,007 | 1,048 | 2,270 |
| Collaboration receivable, current and non-current - related party | -25,359 | 24,491 | -23,585 | -24,938 |
| Other receivables | 16 | -1,563 | -869 | -625 |
| Prepaid expenses and other current assets | -195 | 386 | -47 | -616 |
| Other assets | NaN | 0 | 0 | 0 |
| Accounts payable | -476 | -702 | 615 | -6,526 |
| Accrued expenses and other current liabilities | -2,436 | -2,231 | 1,082 | -10,997 |
| Deferred revenue, current and non-current | 0 | -12,575 | 0 | -12 |
| Deferred revenue - related party, current and non-current | -258 | -2,125 | -3,048 | -16,901 |
| Other long-term liabilities | NaN | 91 | 0 | 0 |
| Operating lease liabilities | NaN | -1,402 | NaN | NaN |
| Operating lease liability | 525 | NaN | -264 | -682 |
| Income taxes | -220 | 220 | 0 | -11 |
| Net cash (used in) provided by operating activities | 15,864 | -8,351 | 17,422 | -21,695 |
| Net decrease in cash and cash equivalents | 15,864 | -8,351 | 17,422 | -21,695 |
| Cash, cash equivalents and restricted cash at beginning of period | 40,265 | 48,616 | 52,889 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 56,129 | 40,265 | 48,616 | NaN |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)